Chronic Kidney Disease Clinical Trial
Official title:
Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate
The goal of this pilot study is to determine whether oral sodium bicarbonate can raise low serum bicarbonate concentration in people without chronic kidney disease (CKD). Participants will take sodium bicarbonate for six weeks, followed by a four week washout period.
CKD affects 25 million Americans and the risks of cardiovascular morbidity, hospitalizations,
and death are substantially higher for people with CKD. Furthermore, 6% of the total Medicare
budget is spent on 600,000 people with end-stage renal disease. Thus, CKD is highly
prevalent, associates with poor outcomes, and is a tremendous financial burden to society.
Apart from treating hypertension and diabetes, there are no therapies that prevent CKD.
However, results from two studies have found that low serum bicarbonate levels increase risk
of developing CKD, which suggests that normalizing low serum bicarbonate may prevent CKD.
One way to raise low serum bicarbonate is by taking sodium bicarbonate. Whether sodium
bicarbonate, which is commonly prescribed to raise low serum bicarbonate in people with CKD,
can raise low bicarbonate in people without CKD is uncertain because the reason bicarbonate
is low in people without CKD is unclear. This is because low bicarbonate by itself cannot
distinguish whether the acid-base abnormality is primary metabolic acidosis or respiratory
alkalosis. The former process is readily corrected with alkali. However, the administration
of alkali in the latter situation may not raise bicarbonate concentration.
Therefore, the purpose of this pilot study is to determine whether oral sodium bicarbonate
can raise low serum bicarbonate in people without renal disease.
The study is a single-arm open label study of 15 individuals without CKD with low serum
bicarbonate concentration. The study duration is 10 weeks. After completing the baseline
visit, participants will take oral sodium bicarbonate (initial dose level: 0.3
milliequivalents per kilogram per day (mEq/kg/d) for 6 weeks (On-treatment period), followed
by a 4 week Off-treatment period. Serum concentrations of sodium bicarbonate will be tested
during the treatment period, at the end of the On-treatment period (Week 6) and at the end of
the Off-treatment period (Week 10).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |